Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration
Authors:
Open Access
- 24 November 2023
- journal article
- research article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 71 (1) , 1-18
Abstract
Duchenne muscular dystrophy (DMD) is a lethal X-linked disease caused by mutations in the dystrophin gene, leading to muscle degeneration and wasting. Electromyography (EMG) is an objective electrophysiological biomarker of muscle fiber function in muscular dystrophies. A novel, DT-DEC01 therapy, consisting of Dystrophin Expressing Chimeric (DEC) cells created by fusing allogeneic myoblasts from normal donors with autologous myoblasts from DMD-affected patients, was assessed for safety and preliminary efficacy in boys of age 6–15 years old (n = 3). Assessments included EMG testing of selected muscles of upper (deltoideus, biceps brachii) and lower (rectus femoris and gastrocnemius) extremities at the screening visit and at 3, 6, and 12 months following systemic–intraosseous administration of a single low dose of DT-DEC01 therapy (Bioethics Committee approval no. 46/2019). No immunosuppression was administered. Safety of DT-DEC01 was confirmed by the lack of therapy-related Adverse Events or Serious Adverse Events up to 22 months following DT-DEC01 administration. EMG of selected muscles of both, ambulatory and non-ambulatory patients confirmed preliminary efficacy of DT-DEC01 therapy by an increase in motor unit potentials (MUP) duration, amplitudes, and polyphasic MUPs at 12 months. This study confirmed EMG as a reliable and objective biomarker of functional assessment in DMD patients after intraosseous administration of the novel DT-DEC01 therapy.Keywords
This publication has 67 references indexed in Scilit:
- The 6‐minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter studyMuscle & Nerve, 2013
- 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular DystrophyPLOS ONE, 2013
- North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophyNeuromuscular Disorders, 2010
- The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observationsMuscle & Nerve, 2010
- Reliability of the North Star Ambulatory Assessment in a multicentric settingNeuromuscular Disorders, 2009
- Multichannel SEMG in clinical gait analysis: A review and state-of-the-artClinical Biomechanics, 2009
- ELECTROPHYSIOLOGICAL ABNORMALITIES IN METABOLIC MYOPATHIES AND NEUROPATHIESActa Neurologica Scandinavica, 2009
- Duchenne muscular dystrophy: an old anesthesia problem revisitedPediatric Anesthesia, 2007
- Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; againPediatric Anesthesia, 2006
- Atypical motor unit potentials in Emery–Dreifuss muscular dystrophy (EDMD)Clinical Neurophysiology, 2005